These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 24408120)

  • 1. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
    Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
    Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
    Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
    Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
    Womack R; Berru F; Panwar B; Gutiérrez OM
    Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of SBR759, a novel calcium-free, iron (III)-based phosphate binder, versus placebo in chronic kidney disease stage V Japanese patients on maintenance renal replacement therapy.
    Fukagawa M; Kasuga H; Joseph D; Sawata H; Junge G; Moore A; Akiba T
    Clin Exp Nephrol; 2014 Feb; 18(1):135-43. PubMed ID: 23670305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
    Takahara Y; Matsuda Y; Takahashi S; Shigematsu T;
    Clin Nephrol; 2014 Sep; 82(3):181-90. PubMed ID: 25079863
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral ferric citrate on serum phosphorus in hemodialysis patients: multicenter, randomized, double-blind, placebo-controlled study.
    Lee CT; Wu IW; Chiang SS; Peng YS; Shu KH; Wu MJ; Wu MS
    J Nephrol; 2015 Feb; 28(1):105-13. PubMed ID: 24840781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
    Yokoyama K; Hashimoto T; Okuda Y; Matsumoto Y; Ito K; Yamada R; Susai H; Nishino N
    Clin Exp Nephrol; 2022 Jul; 26(7):688-699. PubMed ID: 35258721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
    Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
    BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of Action and Clinical Attributes of Auryxia
    Ganz T; Bino A; Salusky IB
    Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
    Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM
    J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.
    Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE;
    Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
    Patel L; Bernard LM; Elder GJ
    Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological profile and clinical findings of a new phosphate binder, ferric citrate hydrate (Riona® Tablets)].
    Miyazaki A; Matsuo A; Iida A; Nishino N; Maeda K; Matsumoto Y; Orui S
    Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):294-304. PubMed ID: 25492366
    [No Abstract]   [Full Text] [Related]  

  • 16. JTT-751 for treatment of patients with hyperphosphatemia on peritoneal dialysis.
    Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Hirakata H
    Nephron Clin Pract; 2014; 128(1-2):135-40. PubMed ID: 25401266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
    Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
    Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Ferric Citrate in Patients with Nondialysis-Dependent CKD and Iron Deficiency Anemia.
    Fishbane S; Block GA; Loram L; Neylan J; Pergola PE; Uhlig K; Chertow GM
    J Am Soc Nephrol; 2017 Jun; 28(6):1851-1858. PubMed ID: 28082519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Ferric Citrate on Hyperphosphatemia among Chinese Patients with Chronic Kidney Disease Undergoing Hemodialysis: A Phase III Multicenter Randomized Open-Label Active-Drug-Controlled Study.
    Wang Y; Chen X; Zhu H; Guo Z; Yang Y; Luo P; He Y; Xu Y; Ji D; Gao X; Sun X; Xing C; Wang Y; Wang X; Zhao S; Guan Y; Lin H; Zhong A; Shui H; Shao F; Lv L; Yan Y; Sun X; Zhang L
    Am J Nephrol; 2023; 54(11-12):479-488. PubMed ID: 37812931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.
    Hanudel MR; Laster M; Ramos G; Gales B; Salusky IB
    Pediatr Nephrol; 2018 Nov; 33(11):2137-2142. PubMed ID: 29956006
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.